"NF-E2-Related Factor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A basic-leucine zipper transcription factor that was originally described as a transcriptional regulator controlling expression of the BETA-GLOBIN gene. It may regulate the expression of a wide variety of genes that play a role in protecting cells from oxidative damage.
| Descriptor ID |
D051267
|
| MeSH Number(s) |
D12.776.260.108.737 D12.776.930.127.737
|
| Concept/Terms |
NF-E2-Related Factor 2- NF-E2-Related Factor 2
- NF E2 Related Factor 2
- Nuclear Factor E2-Related Factor 2
- Nuclear Factor E2 Related Factor 2
- Nfe2l2 Protein
- Nuclear Factor (Erythroid-Derived 2)-Like 2 Protein
|
Below are MeSH descriptors whose meaning is more general than "NF-E2-Related Factor 2".
Below are MeSH descriptors whose meaning is more specific than "NF-E2-Related Factor 2".
This graph shows the total number of publications written about "NF-E2-Related Factor 2" by people in this website by year, and whether "NF-E2-Related Factor 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 5 | 0 | 5 |
| 2009 | 4 | 0 | 4 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 5 | 1 | 6 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 3 | 3 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 4 | 5 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 3 | 4 |
| 2024 | 2 | 3 | 5 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "NF-E2-Related Factor 2" by people in Profiles.
-
Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 Oct 01; 31(19):4184-4195.
-
Biliverdin reductase A is a major determinant of protective NRF2 signaling. Proc Natl Acad Sci U S A. 2025 Oct 07; 122(40):e2513120122.
-
Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders. Nat Biotechnol. 2025 Oct; 43(10):1624-1627.
-
Transcriptional coactivation of NRF2 signaling in cardiac fibroblasts promotes resistance to oxidative stress. J Mol Cell Cardiol. 2024 Sep; 194:70-84.
-
Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer. Nat Metab. 2024 Jul; 6(7):1310-1328.
-
Metaplastic regeneration in the mouse stomach requires a reactive oxygen species pathway. Dev Cell. 2024 05 06; 59(9):1175-1191.e7.
-
Genome-wide p63-Target Gene Analyses Reveal TAp63/NRF2-Dependent Oxidative Stress Responses. Cancer Res Commun. 2024 02 01; 4(2):264-278.
-
An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis. Circ Res. 2023 06 23; 133(1):25-44.
-
Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 06; 128(11):2013-2024.
-
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 04 03; 29(7):1344-1359.